Advertisement
Advertisement
April 2, 2026
Feasibility Trial Begins for Fluidx’s Ultra Embolic Gel in Treatment of Hypervascular Tumors and Blood Vessels
KEY TAKEAWAYS
- Fluidx’s Ultra embolic gel is intended for embolization of hypervascular tumors and blood vessels in peripheral vasculature.
- Andrew Holden, MD, leads the feasibility trial for the device in New Zealand.
- First case was successful treatment of an angiomyolipoma tumor.
April 2, 2026—Fluidx Medical Technology, Inc. announced that the first patient has been treated with the company’s Ultra embolic gel in a feasibility trial of the device conducted in New Zealand.
According to Fluidx, the Ultra gel is intended for embolization of hypervascular tumors and blood vessels to occlude blood flow for controlling bleeding in the peripheral vasculature. The device was successfully used in the treatment of an angiomyolipoma tumor, stated the company.
The feasibility study’s Principal Investigator is Andrew Holden, MD, of Auckland City Hospital in Auckland, New Zealand.
“We are pleased with how controlled the material delivery was,” commented Dr. Holden in the Fluidx press release. “A testament to the technology, we felt comfortable delivering it in a difficult anatomical setting. We could see the material very well as it filled the vessel segment, completely blocking blood flow to the target area.”
Advertisement
Advertisement
